E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pazients with severe or moderatly severe hemophilia A (baseline factor VIII < or =2% of normal) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061992 |
E.1.2 | Term | Haemophilia |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 hours) with that alternate prophylaxis (20-80 IU/kg every 72 hours) 2. To compare the rate of bleeding between the on-demand regimen and the prophylactic regimens 3. To compare the weight-adjusted consumption of ADVATE rAHF-PFM between the 2 prophylactic regimens 4. To determine the efficacy of ADVATE rAHF-PFM for the control of bleeding episodes throughout the study |
|
E.2.2 | Secondary objectives of the trial |
5. To determine the pharmacokinetic parameters for ADVATE rAHF-PFM utilizing at least 3 lots of the study product 6. To determine the immunogenicity of ADVATE rAHF-PFM 7. To determine the safety and toxicity of ADVATE rAHF-PFM 8. To determine differences in HRQoL between the 2 prophylaxis regimens and changes between the on-demand treatment and prophylactic regimens |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.The subject or the subject`s legally authorized representative has provided written IC 2.the subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level < or = 2% of normal, as tested at screening 3. the subject has a documented history of at least 150 exposure days to factor VIII concentrates. 4. The subject is within 7 to 65 years of age. 5.the subject has a Karnofsky performance score >60 6.the subject is HIV- or is HIV+ with a CD4 count> or = 400 cells/mm3 7.The subject has been under the care of the study site for at least 24 months prior to enrollment 8.the subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment. 9. the subject has a documented history of at least 12 joint hemorrhages in the 12 months immediately prior to enrollment. 10. the subject resides within the coverage area of the mobile compliance device, coverage area will be determined at screening. |
|
E.4 | Principal exclusion criteria |
1.the subject has a known hypersensitivity to factor VIII concentrates or mouse or hamster proteins 2.The subject has an history of factor VIII inhibitors with a titer > or = 0.6 BU at any time prior to screening. 3.the subject has a detectable factor VIII inhibitor at screening with a titer > or = 0,4 BU in the central laboratory. 4.the subject has severe chronic liver disease as evidenced by INR>1.4, hypoalbuminemia, portal vein hypertension and hystory of esophageal varices. 5.has been diagnosed with an inherited or aquired hemostatic defect other than hemophilia A (e. g. qualitative platelet defect or von Willebrand`s Disease) 6.the subject has been treated during the last 60 days prior to or is being treated at screening/enrollment with an immunomodulating drug. 7.has participated in another investigational study within 30 days of enrollment 8. has previously participated in a clinical study with ADVATE rAHF-PFM. 9.his/her clinical conditions may require a moderate or major surgery during the period of his/her participation in the study (estimated blood loss > or = 500 ml). 10.the subject is female of childbearing potential with a positive pregnancy test. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 hours) with that alternate prophylaxis (20-80 IU/kg every 72 hours) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
- same IMP used at different dosage |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |